After the progression of this study, another phase II trial, HERTHENA-Lung01 (clinical trial information: NCT04619004), is currently undergoing, which is investigating the effect of the HER3-DXd in previously treated patients with metastatic or locally advanced EGFR-mutated NSCLC after failure of third-generation TKIs. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.